Table 3.

Multivariable predictors of baseline characteristics correlated with changes in office and ambulatory systolic blood pressure

Covariates	Estimate (95% CI)a	P-value
Office SBP
12 months
Baseline office SBP	−0.7 (−0.7 to −0.6)	<0.001
Heart failure	−2.8 (−6.0 to 0.4)	0.090
Aldosterone antagonists	3.0 (0.7–5.3)	0.012
Alpha-adrenergic blocker	2.5 (0.3–4.6)	0.024
Direct-acting vasodilators	3.4 (0.3–6.4)	0.030
24 months
Baseline office SBP	−0.7 (−0.7 to −0.6)	<0.001
Aldosterone antagonists	5.0 (2.2–7.9)	<0.001
Alpha-adrenergic blocker	3.8 (1.2–6.3)	0.004
Direct-acting vasodilators	7.0 (3.2–10.7)	<0.001
36 months
Baseline office SBP	−0.7 (−0.8 to −0.7)	<0.001
Age	−0.1 (−0.2 to 0.0)	0.074
Body mass index	0.2 (−0.0 to 0.5)	0.094
Angiotensin receptor blockers	−3.1 (−6.1 to −0.1)	0.041
Direct renin inhibitors	10.8 (4.0–17.5)	0.002
Beta blockers	−4.0 (−7.3 to −0.7)	0.016
Alpha-adrenergic blocker	6.2 (3.2–9.2)	<0.001
Direct-acting vasodilators	5.0 (0.5–9.6)	0.031
24-h ambulatory SBP
12 months
Baseline ambulatory SBP	−0.5 (−0.6 to −0.4)	<0.001
Baseline ambulatory DBP	−0.1 (−0.2 to 0.0)	0.059
Centrally acting sympatholytics	2.7 (0.7–4.7)	0.009
24 months
Baseline ambulatory SBP	−0.6 (−0.7 to −0.5)	<0.001
Baseline number of medication classes	1.4 (0.3–2.4)	0.009
36 months
Baseline ambulatory SBP	−0.7 (−0.8 to −0.6)	<0.001
Age	−0.2 (−0.4 to −0.0)	0.011
Current smoker	7.3 (1.1–13.5)	0.022

^aEstimate is multivariable linear regression estimate.

CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure.